- CE approval for PEEK-based implant from Evonik
- Help for patients with liver disorders and congestive heart failure
The newly-developed ALFAPump™ System from Sequana Medical Switzerland helps patients suffering from excessive fluid in their abdomen: the battery-operated pump implant is based on the PEEK polymer VESTAKEEP® from Evonik Industries and has received CE approval. It pumps the excessive fluid from the abdominal cavity into the bladder, from which it can be excreted by the patient in the natural manner. Up to now, the water has had to be drained using painful paracentesis during regular doctor's appointments. Patients with liver disorders, congestive heart failure and certain types of cancer are particularly affected by ascites. The new system consists of a subcutaneously implanted pump and a catheter system: one catheter connects the abdomen to the pump, while the second connects the pump to the bladder.
The new technology is made possible thanks to the use of VESTAKEEP® PEEK, a polyether ether ketone which is particularly characterized by its biocompatibility and biostability. In contrast to metal, the ion content of VESTAKEEP® PEEK is virtually zero, thus preventing shift reactions with the body. What's more, the PEEK implant is considerably lighter than a comparable metal implant. The VESTAKEEP® PEEK iGrades are specifically suited to long-term use in the human body and can also be made transparent to X-ray on request, so that they cannot be seen on X-rays.
"The ALFAPump™ System not only improves the quality of life for patients but also represents a cost-effective solution," explains Dr. Noel Johnson, CEO at Sequana Medical. Marc Knebel, Business Management Director at VESTAKEEP® Medical & Implants, adds: "The ALFAPump™ System is a perfect example of the many benefits of PEEK compared to metal in this field. Other areas, such as spinal implants, can also benefit from these advantages."
The high processability of PEEK is a further advantage of its use: VESTAKEEP® PEEK polymer can be manufactured using either the injection molding or cutting procedures, thereby supporting freedom of design in the development of new implant technology.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health and nutrition, resource efficiency and globalization. In 2010 about 80 percent of the Group’s chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.